Elective Cardiac Surgery Clinical Trial
— REFRESHOfficial title:
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
NCT number | NCT02566525 |
Other study ID # | 2015-001 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2015 |
Est. completion date | December 2016 |
Verified date | July 2021 |
Source | CytoSorbents, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.
Status | Completed |
Enrollment | 52 |
Est. completion date | December 2016 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Elective, cardiac surgery requiring cardiopulmonary bypass with anticipated duration of >180 minutes Exclusion Criteria: - Platelet count < 20,000/ uL - Body mass index <18 - Pregnant women - Life expectancy of <14 days - End stage organ disease - Active infection - Undergoing cardiac transplant or ventricular assist device explant, isolated primary coronary artery bypass grafting (CABG) or single valve procedure - Contraindication to anticoagulation with heparin - Declined informed consent |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland | Baltimore | Maryland |
United States | Cooper University Hospital | Camden | New Jersey |
United States | Baylor College of Medicine | Houston | Texas |
United States | University of Kentucky | Lexington | Kentucky |
United States | Columbia University | New York | New York |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania |
United States | Baystate Medical | Springfield | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
CytoSorbents, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Complement Factor C3a - 2 Hours Post Start of CPB | Change in complement factor C3a - Sampling at 2 hours post start of CPB | 2 hours post start of cardiac bypass | |
Other | Change in Complement Factor C3a - 3 Hours Post Start of CPB | Change in complement factor C3a - Sampling at 3 hours post start of CPB | 3 hours post start of CPB | |
Other | Change in Complement Factor C5a - 2 Hours Post Start of CPB | Change in complement factor C5a - Sampling at 2 hours post start of CPB, change from baseline | 2 hours post start of cardiac bypass | |
Primary | Assessment of Serious Device Related Adverse Events | The primary safety endpoint of this trial was to determine the product safety profile through the assessment of serious device related AEs through discharge from the ICU. | From time of enrollment through ICU discharge (e.g. ICU stay of approximately 4 days) | |
Secondary | Time in the ICU | Days in ICU, Post Surgery | From the end of cardiopulmonary bypass procedure through ICU discharge (e.g. ICU stay of approximately 4 days) | |
Secondary | 30 Day All Cause Mortality | Mortality within 30 Days of Surgery | From time of enrollment through 30 days post procedure | |
Secondary | Adverse Event Rates | Total number of Serious Adverse Events | through 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02838524 -
Acceptable Range of Inspiratory Effort During Mechanical Ventilation
|
||
Completed |
NCT00879931 -
Influence of Corticoids on Renal Function in Cardiac Surgery
|
Phase 2 | |
Recruiting |
NCT05662501 -
Pleiades Safety and Feasibility Study
|
N/A | |
Completed |
NCT02407873 -
Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery
|
N/A | |
Not yet recruiting |
NCT01418521 -
Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery
|
Phase 4 | |
Completed |
NCT01748266 -
Microcirculation of the Thenar Eminence
|
N/A | |
Terminated |
NCT03384875 -
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery
|
N/A |